Resonant Therapeutics, Inc.
Resonant has a pipeline of 1st-in-class antibodies in preclinical development as ADCs and other formats. Seeking potential partners and investors.
)
January 11-14, 2027 | San Francisco
January 11-14, 2027 | San Francisco
)
)
January 11-14, 2027 | San Francisco
){kind=logo}
){kind=logo}
)